Kala Pharmaceuticals Inc.

NASDAQ: KALA · Real-Time Price · USD
3.74
-0.23 (-5.79%)
At close: May 01, 2025, 3:58 PM
3.72
-0.53%
After-hours: May 01, 2025, 03:58 PM EDT
-5.79%
Bid 3.5
Market Cap 24.13M
Revenue (ttm) n/a
Net Income (ttm) -38.51M
EPS (ttm) -10.15
PE Ratio (ttm) -0.37
Forward PE -0.92
Analyst Buy
Ask 4.2
Volume 27,173
Avg. Volume (20D) 64,965
Open 3.79
Previous Close 3.97
Day's Range 3.71 - 4.01
52-Week Range 2.92 - 11.20
Beta -1.72

About KALA

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye ...

Sector Healthcare
IPO Date Jul 20, 2017
Employees 38
Stock Exchange NASDAQ
Ticker Symbol KALA
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for KALA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 301.07% from the latest price.

Stock Forecasts
2 months ago
-31.62%
KALA BIO shares are trading lower after the compan... Unlock content with Pro Subscription
10 months ago
+40.22%
KALA BIO shares are trading higher. The company announced a $12.5 million private placement.